TY - CHAP
T1 - Clinical significance of long noncoding RNAs in breast cancer patients
AU - Awasthee, Nikee
AU - Shekher, Anusmita
AU - Rai, Vipin
AU - Baruah, Pranjal K.
AU - Sharma, Anurag
AU - Challagundla, Kishore B.
AU - Gupta, Subash C.
N1 - Funding Information:
The work was supported in part by the Indian Council of Medical Research, New Delhi in SCG’s laboratory (5/13/51/2020/NCD-III). Dr. Challagundla’s laboratory is supported in whole or part by NIH/NCI grant CA197074, Buffet Pilot & Pediatric Cancer Research Group Grants at UNMC. Sharma’s laboratory is supported by Nitte Research Grant (NU/Dr/NUFR1/NUCSER/2019–20/01).
Publisher Copyright:
© 2022 Elsevier Inc. All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Breast cancer is one of the commonly diagnosed cancers in women globally. The long noncoding RNAs (lncRNAs) belong to the category of noncoding RNAs. The lncRNAs are equal to or more than 200 nucleotides in length. Accumulating evidence over the last 5 years has indicated that lncRNAs regulate crucial steps of tumorigenesis in multiple cancer types. Because of high dysregulation, specificity, and sensitivity in the detection, lncRNAs possess the potential of diagnostic and prognostic marker for breast cancer. The commonly identified lncRNAs in breast cancer include antisense ncRNA in the INK4 locus, breast cancer antiestrogen resistance 4, differentiation antagonizing nonprotein-coding RNA, H19-imprinted maternally expressed transcript, hypoxia-inducible factor 1A-antisense RNA 2, HOX transcript antisense RNA, metastasis-associated lung adenocarcinoma transcript 1, miR-503 host gene, terminal differentiation-induced ncRNA, TROJAN, and urothelial cancer-associated 1. The most common techniques used for elucidating the functions of lncRNAs in breast cancer patients include reverse transcription-quantitative polymerase chain reaction, next-generation sequencing, RNA-sequencing, microarray, TILING array, serial analysis of gene expression, cap analysis gene expression, and computational methods. The clinical specimens used to detect lncRNAs in patients include serum, plasma, tissues, urine, and saliva. The lncRNAs are reported to modulate multiple cell signaling pathways in breast cancer patients. The dysregulation in lncRNA expression is also one of the mechanisms by which breast cancer cells develop resistance to therapeutic agents. Thus breast cancer cells could also be sensitized to the therapeutic agents by targeting lncRNAs. The common strategies for targeting lncRNAs include the use of small molecules, antisense oligonucleotides, and RNA interference (RNAi) technology. The focus of this chapter is to review the potential of lncRNAs in breast cancer patients.
AB - Breast cancer is one of the commonly diagnosed cancers in women globally. The long noncoding RNAs (lncRNAs) belong to the category of noncoding RNAs. The lncRNAs are equal to or more than 200 nucleotides in length. Accumulating evidence over the last 5 years has indicated that lncRNAs regulate crucial steps of tumorigenesis in multiple cancer types. Because of high dysregulation, specificity, and sensitivity in the detection, lncRNAs possess the potential of diagnostic and prognostic marker for breast cancer. The commonly identified lncRNAs in breast cancer include antisense ncRNA in the INK4 locus, breast cancer antiestrogen resistance 4, differentiation antagonizing nonprotein-coding RNA, H19-imprinted maternally expressed transcript, hypoxia-inducible factor 1A-antisense RNA 2, HOX transcript antisense RNA, metastasis-associated lung adenocarcinoma transcript 1, miR-503 host gene, terminal differentiation-induced ncRNA, TROJAN, and urothelial cancer-associated 1. The most common techniques used for elucidating the functions of lncRNAs in breast cancer patients include reverse transcription-quantitative polymerase chain reaction, next-generation sequencing, RNA-sequencing, microarray, TILING array, serial analysis of gene expression, cap analysis gene expression, and computational methods. The clinical specimens used to detect lncRNAs in patients include serum, plasma, tissues, urine, and saliva. The lncRNAs are reported to modulate multiple cell signaling pathways in breast cancer patients. The dysregulation in lncRNA expression is also one of the mechanisms by which breast cancer cells develop resistance to therapeutic agents. Thus breast cancer cells could also be sensitized to the therapeutic agents by targeting lncRNAs. The common strategies for targeting lncRNAs include the use of small molecules, antisense oligonucleotides, and RNA interference (RNAi) technology. The focus of this chapter is to review the potential of lncRNAs in breast cancer patients.
KW - Breast cancer
KW - Carcinogenesis
KW - Diagnosis
KW - Long noncoding RNA
KW - Prognosis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85129690229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129690229&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-824550-7.00008-4
DO - 10.1016/B978-0-12-824550-7.00008-4
M3 - Chapter
AN - SCOPUS:85129690229
SN - 9780128245514
SP - 285
EP - 296
BT - Clinical Applications of Noncoding RNAs in Cancer
PB - Elsevier
ER -